Dose: 50 to 200 mg
Single Dose: 120 (125)
Frequency: As recommended.
Route: PO
Instructions: For metastatic breast carcinoma

. It is of Synthetic origin and belongs to Anabolic steroid. . The Molecular Weight of Methyltestosterone is 302.46.

Methyltestosterone is contraindicated in conditions like Breast cancer,Pregnancy,Prostate cancer.

The severe or irreversible adverse effects of Methyltestosterone, which give rise to further complications include Nausea, Atrophy, Atrophy, GI upsets.The symptomatic adverse reactions produced by Methyltestosterone are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Anxiety, Depression, Acne, Hirsutism, Gynecomastia, Virilization, Amenorrhea, Penile erection, Baldness, Oligospermia, Libido.

Methyltestosterone is primarily indicated in conditions like Hormone replacement therapy, Hypogonadotrophic hypogonadism, Primary hypogonadism, and can also be given in adjunctive therapy as an alternative drug of choice in Metastatic carcinoma of breast.

No data regarding the interactions of Methyltestosterone was found.

Liver Function Test (LFT)

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Tablets Store Between 20°C-25°C.

In patients with breast cancer, androgen therapy may cause hypercalcemia by stimulating osteolysis. In this case, the drug should be discontinued. Cholestatic hepatitis and jaundice occur with 17-alpha-alkylandrogens at a relatively low dose. If cholestatic hepatitis with jaundice appears or if liver function tests become abnormal, the androgen should be discontinued and the etiology should be determined. Drug-induced jaundice is reversible when the medication is discontinued. Geriatric patients treated with androgens may be at an increased risk for the development of prostatic hypertrophy and prostatic carcinoma. Edema with or without congestive heart failure may be a serious complication in patients with preexisting cardiac, renal, or hepatic disease. In addition to discontinuation of the drug, diuretic therapy may be required.